Guardant Health, Inc. Common Stock
GHGuardant Health, Inc. is a precision oncology company that develops blood tests for cancer detection and management. Founded in 2012, it focuses on liquid biopsy technologies to provide non-invasive cancer diagnostics, monitoring, and treatment guidance. The company's products are used for early detection, treatment selection, and tracking disease progression in various types of cancer.
Company News
The global ovarian cancer diagnostics market is valued at USD 4.92 billion in 2025 and is projected to reach USD 8.08 billion by 2035, growing at a CAGR of 5.06%. Growth is driven by rising ovarian cancer incidence, increasing adoption of AI-powered imaging, biomarker testing, and precision oncology diagnostics. North America leads with 41.2% mar...
Grail, a leader in multi-cancer early detection (MCED) testing, could be poised for significant growth as its Galleri test shows promising clinical trial results. The company awaits FDA approval and potential insurance reimbursement, which could unlock a $50 billion market opportunity. However, the stock remains high-risk due to unprofitability a...
The global AI in cancer diagnostics market is experiencing rapid growth, projected to expand from $0.79 billion in 2025 to $0.96 billion in 2026 (20.2% CAGR), reaching $1.97 billion by 2030. Growth is driven by advancements in deep learning, AI-powered imaging systems, rising cancer prevalence, and collaborations between AI developers and medical...
Guardant Health received FDA approval for its Guardant360 Liquid CDx test, an expanded liquid biopsy panel that is now the largest FDA-approved in its category. The test evaluates a genomic footprint 100 times wider than the previous version, combines genomic and epigenomic insights from a single blood sample, and can deliver results in as little...
The global colorectal cancer diagnostics and therapeutics market is projected to grow from USD 35 billion in 2025 to USD 73 billion by 2034 at a CAGR of ~9%. Growth is driven by rising colorectal cancer prevalence, increased screening awareness, advancements in non-invasive diagnostics (liquid biopsy, stool-based DNA tests), and emerging targeted...
